Tranexamic acid and traumatic brain injuries

Katarina Sanford, Sarah Garcia

JAAPA. 2020 Dec;33(12):53-54

Abstract

The CRASH-3 trial examined the use of tranexamic acid (TXA) in patients with intracranial bleeding secondary to traumatic brain injury. The trial demonstrated that TXA, an antifibrinolytic medication, reduces mortality in patients with mild to moderate head injuries. However, because of the trial's multiple limitations, TXA cannot yet be called the gold standard.